New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
09:59 EDTSQNM, WLPWellpoint deems Sequenom pre-natal tests medically necessary for some patients
In a medical policy update with an effective date of Dec. 19, 2012, health insurer Wellpoint (WLP) stated that it views cell-free fetal DNA-based prenatal screening for fetal aneuploidies, including but not limited to Trisomy 13, Trisomy 18 and Trisomy 21, medically necessary for its members when certain criteria are met. Wellpoint stated there are currently several commercially available laboratory developed tests which analyze circulating cell-free DNA to identify increased representation of various chromosomes, including but not necessarily limited to the Sequenom's (SQNM) MaterniT21 Test and its MaterniT21 Plus Test, among others from Verinata Health and Aria Diagnostics. In early morning trading, shares of Sequenom rose 32c, or 6.84%, to $4.96, with the strength being attributed by some to Wellpoint's approval. Reference Link
News For SQNM;WLP From The Last 14 Days
Check below for free stories on SQNM;WLP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
14:41 EDTSQNMFDA draft lab tests guidelines not as bad as feared, says Piper Jaffray
Subscribe for More Information
07:50 EDTWLPWellPoint price target raised to $130 from $120 at UBS
Subscribe for More Information
July 30, 2014
08:39 EDTSQNMSequenom should be bought following solid Q2, says Maxim
Subscribe for More Information
05:54 EDTWLPWellPoint sees FY14 adjusted EPS over $8.60, consensus $8.58
Sees FY14 revenue greater than $73.5M, consensus $73.45B. Medical membership is now expected to be in the range of 37.05M37.15M. Fully insured membership is now expected to be in the range of 14.55M14.6M and self-funded membership is now expected to be in the range of 22.5M22.55M.
05:51 EDTWLPWellPoint reports Q2 EPS ex-items $2.44, consensus $2.26
Reports Q2 revenue $18.23B, consensus $18.23B. Medical enrollment increased sequentially by 328,000 members, or 0.9%, totaling approximately 37.3M members as of June 30.
July 29, 2014
18:35 EDTSQNMOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTSQNMSequenom reports Q2 adjusted EPS (7c), consensus (11c)
Subscribe for More Information
16:32 EDTSQNMSequenom enters license agreement with Mayo Medical Laboratories
Subscribe for More Information
15:53 EDTWLPNotable companies reporting before tomorrow's open
Subscribe for More Information
15:26 EDTWLPWellPoint August volatility elevated into Q4 and outlook
Subscribe for More Information
10:29 EDTWLPWellPoint shares defended at UBS
Subscribe for More Information
July 28, 2014
07:51 EDTWLPWellPoint price target raised to $130 from $112 at Cowen
Subscribe for More Information
July 25, 2014
12:11 EDTWLPWellCare profit warning sinks managed care names
A number of managed care names are falling after one of the companies in the sector, WellCare (WCG), preannounced significantly weaker than expected results. UBS, however, recommends using the weakness in the sector as a buying opportunity. WHAT'S NEW: WellCare, which specializes in managing Medicaid and Medicare plans, preannounced a second quarter per share loss of 7c, excluding certain items. Analysts on average expected the company to report a per share profit of 90c. The company's revenue came in slightly above expectations. WellCare cut its full-year earnings per share guidance to $2.20-$2.50 from $4.40-$4.75. The company said recipients of a new Medicaid program in Florida utilized more medical services than expected since the company began administering the program in May. Additionally, the company took an impairment charge related to an acquisition and it had an unfavorable reserve development. ANALYST REACTION: The factors cited by WellCare for the cut in its guidance appear to be specific to that company, UBS analyst A.J. Rice wrote. Meanwhile, data from other companies that administer Medicaid plans indicate that the increased utilization costs in that state are also specific to WellCare, Rice contended. For example, Centene (CNC) reported Q2 results earlier this week and indicated that utilization trends for newly covered beneficiaries in Florida was largely in line with expectations, while UnitedHealth (UNH) said its Medicaid business had performed well last quarter, the analyst stated. Additionally, WellCare said that its higher than expected medical utilization costs had been caused primarily by drug costs that exceeded its forecast, Rice stated. Since drug costs tend to be known relatively quickly, United Health and Centene would have divulged any issues with drug costs in conjunction with their Q2 results, Rice said. The analyst recommended that investors buy Aetna (AET), Cigna (CI), United Health and WellPoint (WLP) on any weakness today. PRICE ACTION: In late morning trading, Aetna fell 1.5% to $83, Cigna lost 1% to $95.50, UnitedHealth lost 1% to $84.50, WellPoint slid 1.5% to $113.50 and Centene tumbled 7% to $74 while WellCare plunged 19% to $62.
10:52 EDTWLPWellCare issues largely company-specific, says UBS
UBS notes that aside from WellCare (WCG), which attributed its lowered guidance to the start-up of its Florida MMA program and other issues, that Centene (CNC), WellPoint (WLP), UnitedHealth (UNH) and Humana (HUM) are the leaders in Medicaid in the state. However, the firm believes a majority of WellCare's issues appear company specific and UBS views any weakness in UnitedHealth, WellPoint, Aetna (AET), or Cigna (CI) as opportunity to buy those four stocks, on all of which it has Buy ratings.
July 24, 2014
06:50 EDTWLPConsumers received $9B in refunds from health insurers, The Hill says
Subscribe for More Information
July 22, 2014
13:46 EDTWLPCourt upholds Obamacare subsidies, NY Times says
Subscribe for More Information
10:43 EDTWLPAppeals court bars subsidies in health care law
A three-judge panel of the D.C. Circuit Court of Appeals struck down part of President Obama's healthcare law by siding today with plaintiffs who argued that the law barred the government from giving subsidies to people in states that chose not to set up their own insurance marketplaces. The appeals court stated, "Because we conclude that the ACA unambiguously restricts the section 36B subsidy to insurance purchased on Exchanges 'established by the State,' we reverse the district court and vacate the IRSs regulation." Twenty-seven states decided against setting up marketplaces, and another nine states partially opted out, according to the Washington Post.
July 21, 2014
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use